Cargando…

Improved Long-Term Survival with Edaravone Therapy in Patients with Amyotrophic Lateral Sclerosis: A Retrospective Single-Center Study in Japan

Reports on the long-term survival effect of edaravone, which was approved for the treatment of amyotrophic lateral sclerosis (ALS) in 2015 in Japan, are rare. Herein, we report our retrospective analysis of 45 consecutive patients with ALS who initially visited our hospital between 2013 and 2018. Of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Houzen, Hideki, Kano, Takahiro, Horiuchi, Kazuhiro, Wakita, Masahiro, Nagai, Azusa, Yabe, Ichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398196/ https://www.ncbi.nlm.nih.gov/pubmed/34451802 http://dx.doi.org/10.3390/ph14080705

Ejemplares similares

Myasthenic Crisis Complicated with Myxedema, Positive for Both Anti-acetylcholine Receptor and Anti-muscle-specific Tyrosine Kinase Antibodies
por: Horiuchi, Kazuhiro, et al.
Publicado: (2017)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis
por: Okada, Masamitsu, et al.
Publicado: (2018)

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis
por: Jayasinghe, Maleesha, et al.
Publicado: (2022)

Validity and reliability of a pilot scale for assessment of multiple system atrophy symptoms
por: Matsushima, Masaaki, et al.
Publicado: (2017)

Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis
por: Takahashi, Ikuko, et al.
Publicado: (2015)

Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients
por: Park, Jin-Mo, et al.
Publicado: (2019)

Role of Edaravone as a Treatment Option for Patients with Amyotrophic Lateral Sclerosis
por: Cho, HaEun, et al.
Publicado: (2020)

Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
por: Al-Chalabi, Ammar, et al.
Publicado: (2021)

How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?
por: Watanabe, Kazutoshi, et al.
Publicado: (2018)

Renal function in amyotrophic lateral sclerosis patients on long-term treatment with edaravone
por: Kakimoto, Asako, et al.
Publicado: (2021)

Magnetic resonance metrics to evaluate the effect of therapy in amyotrophic lateral sclerosis: the experience with edaravone
por: Distaso, Eugenio, et al.
Publicado: (2021)

Assessment of Therapeutic Response of Edaravone and Riluzole Combination Therapy in Amyotrophic Lateral Sclerosis Patients
por: Samadhiya, Swapnil, et al.
Publicado: (2022)

Investigating Edaravone Use for Management of Amyotrophic Lateral Sclerosis (ALS): A Narrative Review
por: Neupane, Purushottam, et al.
Publicado: (2023)

Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System
por: Vu, Michelle, et al.
Publicado: (2020)

Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone
por: Han, Hee Jo, et al.
Publicado: (2022)

Effects of the Edaravone, a Drug Approved for the Treatment of Amyotrophic Lateral Sclerosis, on Mitochondrial Function and Neuroprotection
por: Cha, Sun Joo, et al.
Publicado: (2022)

Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis
por: Nourelden, Anas Zakarya, et al.
Publicado: (2023)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study
por: Park, Jin-Mo, et al.
Publicado: (2022)

Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

In silico studies reveal structural deviations of mutant profilin-1 and interaction with riluzole and edaravone in amyotrophic lateral sclerosis
por: Sadr, Ahmad Shahir, et al.
Publicado: (2021)

Prevalence and Incidence of Amyotrophic Lateral Sclerosis in Japan
Publicado: (2014)

Long‐term edaravone efficacy in amyotrophic lateral sclerosis: Post‐hoc analyses of Study 19 (MCI186‐19)
por: Shefner, Jeremy, et al.
Publicado: (2019)

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment
por: Genge, Angela, et al.
Publicado: (2022)

Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: A parallel-group single-blind trial
por: Eishi-Oskouei, Alireza, et al.
Publicado: (2021)

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients
por: Abe, Koji, et al.
Publicado: (2014)

Descriptive Epidemiology of Amyotrophic Lateral Sclerosis in Japan, 1995-2001
por: Okamoto, Kazushi, et al.
Publicado: (2005)

Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis
por: Aizawa, Hitoshi, et al.
Publicado: (2021)

Contradictory Responses to the COVID-19 Pandemic in Amyotrophic Lateral Sclerosis Patients and Their Families and Caregivers in Japan
por: Yanagihashi, Masaru, et al.
Publicado: (2021)

Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009)

Investigation of non-motor symptoms in patients with amyotrophic lateral sclerosis
por: Hirayama, Takehisa, et al.
Publicado: (2022)

Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS‐R item scores in pivotal study MCI186‐19
por: Brooks, Benjamin Rix, et al.
Publicado: (2021)

Amyotrophic lateral sclerosis and neuroregeneration
Publicado: (2012)

Mimickers of Amyotrophic Lateral Sclerosis
por: Dubey, Ayush, et al.
Publicado: (2019)

Destination Amyotrophic Lateral Sclerosis
por: Keon, Matt, et al.
Publicado: (2021)

Prionoids in amyotrophic lateral sclerosis
por: Gosset, Philippe, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis and cerebellum
por: Kabiljo, Renata, et al.
Publicado: (2022)

Dysautonomia in Amyotrophic Lateral Sclerosis
por: Oprisan, Alexandra L., et al.
Publicado: (2023)

Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms
por: Kano, Osamu, et al.
Publicado: (2018)

Amyotrophic lateral sclerosis with a sudden-onset history
por: Kanbayashi, Takamichi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vdtp1uscdr7uej5j85cmoabjcj